30 results about "Echovirus" patented technology

The invention discloses new application of scullcapflavone in preparing a medicament for treating enterovirus infection, in particular new application of scullcapflavone in preparing a medicament for treating or preventing a hand-foot-and-mouth disease caused by enterovirus infection. The scullcapflavone comprises an extract of baicalein, baicalin or scutellaria baicalensis general flavone; and the enterovirus indicates a coxsackie virus A group, a coxsackie virus B group, echovirus or enterovirus EV71 which causes the hand-foot-and-mouth disease. The scullcapflavone as an active substance is mixed with a pharmaceutically allowable excipient and made into a preparation which can be accepted by a patient and can be used for treating and preventing the hand-foot-and-mouth disease by injection administration, mucosa administration, oral administration or inhalation and has obvious treating effect and high safety.

The invention discloses a traditional Chinese medicine composition for treating viral respiratory tract infection and a preparation method thereof. The composition comprises the following raw medicinal materials in parts by weight: 3-20 parts of honey-fried ephedra, 3-20 parts of flos farfarae, 5-25 parts of schizonepeta spike, 5-20 parts of radix asteris, 5-15 parts of apricot kernel, 5-20 parts of roasted perilla seed, 3-15 parts of rhizoma anemarrhenae, 3-15 parts of bulbus fritillariae thunbergii, 5-25 parts of fructus arctii, and 2-15 parts of liquorice. The raw medicinal materials are matched with auxiliary materials and a flavoring agent to be directly or indirectly made into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of dosage forms via conventional processes. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, hand, foot and mouth virus, adenovirus, parainfluenza virus, echovirus, coxsackievirus and the like.

The invention discloses a siRNA echovirus delivery system with a shell-core structure. The core of the structure refers to polyarginine-modified or polyhistidine-modified chitosan coated siRNA, and the shell refers to albumin modified by polypeptide containing an RGD group sequence and by arginine. The delivery system can recognize tumor cells in a targeted mode, after the system enters in an endosome-lysosome acid environment, the protein shell is removed, the exposed core can escape from the endosome-lysosome, and under the intracellular GSH reduction condition, siRNA is released. The delivery system is good in stability, high in gene loading capacity and excellent in active target performance, and can significantly improve the gene silencing effect of siRNA and effectively inhibit the growth and metastasis of tumor cells.

The invention discloses a traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and a preparation method thereof. The composition comprises the following active pharmaceutical ingredients in parts by weight: 5-25g of perilla leaf, 5-25g of tatarian aster root, 5-25g of Chinese thorowax root, 5-25g of schizonepeta spike, 5-25g of great burdock achene, 5-25g of apricot seed and 1-15g of liquoric root. The active pharmaceutical ingredients can be matched with excipients and a flavoring agent to be directly or indirectly prepared into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of formulations via conventional process steps. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, adenovirus, parainfluenza virus, enteric cytopathogenichuman orphan virus, Coxsackie virus and the like.

The invention discloses an enteric cytopathogenic human orphan virus 6-type VP1 protein specific epitope, a fusion protein of the enteric cytopathogenic human orphan virus 6-type VP1 protein specific epitope and a preparation method and use of the fusion protein and relates to the field of a gene engineering technology, a vaccine and a diagnostic reagent. The preparation method comprises analyzing an enteric cytopathogenic human orphan virus 6-type surface protein VP1 amino acid sequence by a computer, and screening strong specific epitope-containing protein fragments comprising 75th-101th amino acids, 127th-141th amino acids, 204th-237th amino acids and 257th-289th amino acids, wherein the four protein fragments are connected by 2 glycines and 1 serine so that the epitope fusion protein is formed. A codon in favor with eucaryotes and prokaryotes is used, a brand new gene sequence of the epitope fusion protein is chemically synthesized, through a gene engineering technology, the enteric cytopathogenic human orphan virus 6-type VP1 protein epitope fusion protein is expressed and prepared and is used for development of an enteric cytopathogenic human orphan virus antibody detection reagent and preparation of an enteric cytopathogenic human orphan virus monoclonal antibody and polyclonal antibody.

New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided.

The invention discloses antitumor application of echo viruses used as oncolytic viruses. The antitumor application particularly includes application of the echo viruses ECHO1, ECHO3, ECHO4, ECHO5, ECHO6, ECHO7, ECHO9, ECHO11 and ECHO25 to lung cancer, colon cancer, prostate cancer, gastric cancer, liver cancer, pancreatic cancer and rhabdomyoma. The antitumor application has the advantages that different levels of oncolytic activity of the different echo viruses for different types of tumor cells are proved, and accordingly the fact that the echo viruses can be used for specifically treating tumor is prompted.

The invention relates to the technical field of pathogen detection, in particular to a universal nucleic acid detection reagent for enteroviruses EV71, CA16 and EV. The universal nucleic acid detection reagent for the enteroviruses EV71, CA16 and EV provided by the invention can tolerate interference of inhibitors, namely cholate and haemachrome due to the addition of an anti-inhibition component;and furthermore, the reagent can be stably stored at 2-8 DEG C and avoids the harsh condition of cryopreservation at -20 DEG C, so that unfreezing is not needed before reaction, and the reaction efficiency is improved. The reagent is suitable for more sample types, such as a throat swab, excrement, a herpes fluid and a cloacal swab when prepared into a kit. A universal primer of the kit covers more serotypes, including coxsackie A, coxsackie B, the enterovirus 71 and an echo virus. The kit has good sensitivity, specificity and repeatability.

The invention provides echovirus type-9 VP1 protein specific antigen epitope and a preparation method and application of a fusion protein thereof, and relates to the fields of genetic engineering technology, vaccines and diagnostic reagents. Computer analysis is carried out on the amino acid sequence of the echovirus type-9 surface protein VP1 to screen out protein fragments containing strong specific antigen epitope, namely 75th amino acid-102nd amino acid, 127th amino acid-140th amino acid, 204th amino acid-237th amino acid and 257th amino acid-300th amino acid, and the four protein fragments are connected through two glycines and one serine to form one antigen epitope fusion protein. Codons preferred by both eukaryon and prokaryote are selected for chemical synthesis of a brand new gene sequence of the antigen epitope fusion protein, the genetic engineering technology is utilized to prepare the antigen epitope fusion protein of the echovirus type-9 VP1 protein by expression, and the antigen epitope fusion protein is used for developing an echovirus antibody detection kit and preparing echovirus monoclonal antibody and polyclonal antibody.

The invention discloses an application of epigallocatechin gallate in preparation of a medicine for treating and/or preventing diseases caused by Epidemic diarrhea virus infection. The EGCG in-vitro anti-Erkovirus effect and mechanism are deeply discussed, the feasibility of the EGCG serving as an Erkovirus treatment medicine is verified, a theoretical basis is provided for research and development of natural products of Erkovirus inhibitors, and the product is expected to be used for treating various diseases caused by Erkovirus infection.

The invention discloses a method for detecting an echovirus type 9 antibody, which takes ECHO9 VP1 recombinant protein as an antigen of an elisa plate, breaks through the limitation that a virus strain is directly inactivated to serve as an antigen to coat the elisa plate in the past or virus strain infected cells are used for preparing an antigen sheet, and meets the requirements of high throughput and safety in preparation of the elisa plate. The kit is beneficial to clinical treatment of sterile encephalitis diseases, and plays an important role in technical support for early discovery and early intervention of sudden epidemic situations caused by ECHO9, epidemiological research and guarantee of health of the masses.

The invention provides application of pepper in preparation of a medicine for treating and/or preventing respiratory virus pneumonia. The invention also discloses a method for effectively inhibiting and/or treating coronavirus, human metapneumovirus, influenza virus, parainfluenza virus, respiratory syncytial virus, measles virus, parotitis virus, rubella virus, adenovirus, cytomegalovirus, coxsackie virus, echovirus, herpes simplex virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus and herpes zoster virus. The invention provides a new choice for clinical treatment of infection of respiratory viruses such as chicken pox-herpes zoster virus or rhinovirus.

The invention discloses a traditional Chinese medicinal composition for treating viral respiratory infection and a preparation method of the traditional Chinese medicinal composition. The composition consists of the following medicinal raw materials in parts by weight: 5-20 parts of folium perillae, 1-15 parts of cortex magnoliae officinalis processed with ginger, 5-25 parts of schizonepeta spikes, 5-20 parts of radix asteris, 5-15 parts of apricot kernels, 5-20 parts of fried fructus perillae, 3-15 parts of rhizoma anemarrhenae, 3-15 parts of bulbus fritillariae thunbergii, 5-25 parts of fructus arctii and 2-15 parts of liquorice root. The medicinal raw materials, in coordination with adjuvants and a flavoring agent, are directly or indirectly prepared into pharmaceutically acceptable dosage forms such as capsules, oral liquid, granules, syrup, tablets, effervescent granules, dropping pills, an aerosol, a spray, gargarisma, mouthwash and the like by virtue of a conventional process. In the clinical field, the traditional Chinese medicinal composition can be used for preventing or treating respiratory virus infectious diseases caused by influenza A viruses, influenza B viruses, rhinoviruses, coronaviruses, respiratory syncytial viruses, hand, foot and mouth viruses, adenoviruses, parainfluenza viruses, echoviruses, Coxsackie viruses and the like.